| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Marc De Hert, Aurélia Mittoux, Yuan He, Joseph Peusken. Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone. European archives of psychiatry and clinical neuroscience. vol 261. issue 4. 2011-10-14. PMID:20820795. |
metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone. |
2011-10-14 |
2023-08-12 |
Not clear |
| Tamara Melnik, Bernardo Garcia Soares, Maria Eduarda Dos Santos Puga, Alvaro Nagib Atalla. Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews. Sao Paulo medical journal = Revista paulista de medicina. vol 128. issue 3. 2011-10-13. PMID:20963366. |
efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews. |
2011-10-13 |
2023-08-12 |
Not clear |
| Jonathan Rabinowitz, Oleksandr Napryeyenko, Benjaminas Burba, Guadalupe Martinez, Nikolay G Neznanov, Tsvi Fischel, Franck J Baylé, Roberto Cavallaro, Enrico Smeraldi, Andreas Schreine. Premorbid functioning and treatment response in recent-onset schizophrenia: prospective study with risperidone long-acting injectable. Journal of clinical psychopharmacology. vol 31. issue 1. 2011-10-13. PMID:21192147. |
premorbid functioning and treatment response in recent-onset schizophrenia: prospective study with risperidone long-acting injectable. |
2011-10-13 |
2023-08-12 |
human |
| Jonathan Rabinowitz, Oleksandr Napryeyenko, Benjaminas Burba, Guadalupe Martinez, Nikolay G Neznanov, Tsvi Fischel, Franck J Baylé, Roberto Cavallaro, Enrico Smeraldi, Andreas Schreine. Premorbid functioning and treatment response in recent-onset schizophrenia: prospective study with risperidone long-acting injectable. Journal of clinical psychopharmacology. vol 31. issue 1. 2011-10-13. PMID:21192147. |
this was a 6-month, open label, multicenter, phase iv trial in recent-onset schizophrenia treated with flexible doses of risperidone long-acting injectable (25-50 mg every 14 days). |
2011-10-13 |
2023-08-12 |
human |
| Simon A Surguladze, Elvina M Chu, Nicolette Marshall, Anthony Evans, Anantha P P Anilkumar, Clive Timehin, Colm McDonald, Christine Ecker, Mary L Phillips, Anthony S Davi. Emotion processing in schizophrenia: fMRI study of patients treated with risperidone long-acting injections or conventional depot medication. Journal of psychopharmacology (Oxford, England). vol 25. issue 6. 2011-09-28. PMID:20360158. |
emotion processing in schizophrenia: fmri study of patients treated with risperidone long-acting injections or conventional depot medication. |
2011-09-28 |
2023-08-12 |
Not clear |
| Simon A Surguladze, Elvina M Chu, Nicolette Marshall, Anthony Evans, Anantha P P Anilkumar, Clive Timehin, Colm McDonald, Christine Ecker, Mary L Phillips, Anthony S Davi. Emotion processing in schizophrenia: fMRI study of patients treated with risperidone long-acting injections or conventional depot medication. Journal of psychopharmacology (Oxford, England). vol 25. issue 6. 2011-09-28. PMID:20360158. |
the sample comprised 16 chronic schizophrenia patients treated with risperidone long-acting injections (rlai), 16 patients treated with conventional antipsychotic depots (conv) and 16 healthy controls (hc). |
2011-09-28 |
2023-08-12 |
Not clear |
| Ana Paula Werneck, Jaime Cecilio Hallak, Eduardo Nakano, Helio Elki. Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine. Psychiatry research. vol 188. issue 3. 2011-09-27. PMID:21596442. |
a retrospective observational study was conducted designed to evaluate time to rehospitalization of patients with schizophrenia discharged on a regimen of oral fga, depot fga, risperidone, olanzapine and amisulpride, other sga, or clozapine, during a three-year follow-up period. |
2011-09-27 |
2023-08-12 |
Not clear |
| Serge Sevy, Delbert G Robinson, Suzanne Sunday, Barbara Napolitano, Rachel Miller, Joanne McCormack, John Kan. Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. Psychiatry research. vol 188. issue 3. 2011-09-27. PMID:21636134. |
olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. |
2011-09-27 |
2023-08-12 |
Not clear |
| Serge Sevy, Delbert G Robinson, Suzanne Sunday, Barbara Napolitano, Rachel Miller, Joanne McCormack, John Kan. Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. Psychiatry research. vol 188. issue 3. 2011-09-27. PMID:21636134. |
the purpose of this study is to compare the efficacy of olanzapine and risperidone for the acute treatment of first-episode schizophrenia patients with cannabis use disorders. |
2011-09-27 |
2023-08-12 |
Not clear |
| T A Hardy, R R Henry, T D Forrester, L A Kryzhanovskaya, G M Campbell, D M Marks, S Mudalia. Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. Diabetes, obesity & metabolism. vol 13. issue 8. 2011-09-16. PMID:21435142. |
impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. |
2011-09-16 |
2023-08-12 |
Not clear |
| T A Hardy, R R Henry, T D Forrester, L A Kryzhanovskaya, G M Campbell, D M Marks, S Mudalia. Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. Diabetes, obesity & metabolism. vol 13. issue 8. 2011-09-16. PMID:21435142. |
to assess changes in insulin sensitivity in non-diabetic adults with schizophrenia or schizoaffective disorder treated with olanzapine or risperidone. |
2011-09-16 |
2023-08-12 |
Not clear |
| Marieke Liem-Moolenaar, Mandana Rad, Stefano Zamuner, Adam F Cohen, Francesca Lemme, Kari L Franson, Joop M A van Gerven, Emilio Merlo Pic. Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men. British journal of clinical pharmacology. vol 71. issue 6. 2011-09-14. PMID:21223356. |
risperidone, commonly used to control agitation and psychotic features in both schizophrenia and alzheimer's disease, is a d(2)/5-ht(2a ) antagonist with low affinity for 5-ht(6) receptors and limited effects on cognitive parameters. |
2011-09-14 |
2023-08-12 |
Not clear |
| Katherine Seto, Jane Dumontet, Mary H H Enso. Risperidone in schizophrenia: is there a role for therapeutic drug monitoring? Therapeutic drug monitoring. vol 33. issue 3. 2011-09-14. PMID:21436762. |
risperidone in schizophrenia: is there a role for therapeutic drug monitoring? |
2011-09-14 |
2023-08-12 |
Not clear |
| Katherine Seto, Jane Dumontet, Mary H H Enso. Risperidone in schizophrenia: is there a role for therapeutic drug monitoring? Therapeutic drug monitoring. vol 33. issue 3. 2011-09-14. PMID:21436762. |
the purpose of this review was to determine whether risperidone warrants therapeutic drug monitoring in patients with schizophrenia. |
2011-09-14 |
2023-08-12 |
Not clear |
| Huafang Li, Qing Rui, Xiaoping Ning, Haiyan Xu, Niufan G. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 4. 2011-09-13. PMID:21315787. |
a comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. |
2011-09-13 |
2023-08-12 |
Not clear |
| Huafang Li, Qing Rui, Xiaoping Ning, Haiyan Xu, Niufan G. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 4. 2011-09-13. PMID:21315787. |
this open-label, rater-blinded, parallel-group study was designed to evaluate noninferiority of paliperidone palmitate (pp), a once-monthly injectable atypical antipsychotic, to once-biweekly risperidone long-acting injectable (ris-lai) in adult chinese patients with acute schizophrenia. |
2011-09-13 |
2023-08-12 |
Not clear |
| Huafang Li, Qing Rui, Xiaoping Ning, Haiyan Xu, Niufan G. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 4. 2011-09-13. PMID:21315787. |
the study demonstrated the noninferiority of pp (50-150 mg eq., flexibly dosed, without oral paliperidone supplementation) to risperidone-lai (25-50 mg, flexibly dosed, with oral risperidone supplementation) for the treatment of acute schizophrenia in adult chinese patients. |
2011-09-13 |
2023-08-12 |
Not clear |
| X S Ren, C Crivera, M Sikirica, R Dirani, S Qian, L E Kazi. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration. Journal of clinical pharmacy and therapeutics. vol 36. issue 3. 2011-09-02. PMID:21062329. |
evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration. |
2011-09-02 |
2023-08-12 |
Not clear |
| X S Ren, C Crivera, M Sikirica, R Dirani, S Qian, L E Kazi. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration. Journal of clinical pharmacy and therapeutics. vol 36. issue 3. 2011-09-02. PMID:21062329. |
in this study, we assessed patterns of health-care utilization following the initiation of risperidone long-acting therapy (rlat), the first and only second generation long-acting injectable antipsychotic agent, in schizophrenia patients within the veterans health administration. |
2011-09-02 |
2023-08-12 |
Not clear |
| Makoto Ishitobi, Hirotaka Kosaka, Ken-Ichi Shukunami, Tetsuhito Murata, Yuji Wad. Comment on "dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia". Journal of clinical psychopharmacology. vol 31. issue 3. 2011-08-29. PMID:21532377. |
comment on "dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia". |
2011-08-29 |
2023-08-12 |
Not clear |